BioMérieux to take control of Japanese joint venture

Sysmex bioMérieux Co was formed in 2008 to bring together bioMérieux’s business and Sysmex’ expertise of the Japanese market.

It involved the manufacture and sale of in vitro diagnostic reagents and medical instruments related to microbes, genes and immunochemistry.

The company promoted and commercialized the whole bioMérieux product range in the country.

BioMérieux had been operating in the Japanese clinical diagnostics and industrial testing market through bioMérieux Japan, a fully-owned subsidiary.

Sysmex will transfer all of its holdings in Sysmex bioMérieux (34% of shares) to bioMérieux.

The distribution agreement relating to bioMérieux products in Japan between Sysmex and Sysmex bioMérieux will also terminate at the end of October.

Sysmex will continue to provide customer service for bioMérieux products until the end of March next year.

BioMérieux will then build its commercial structure to take over activities previously led by Sysmex.

Sysmex has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs about 8,000 people.

BioMérieux is in more than 150 countries through 42 subsidiaries and a network of distributors. In 2016, revenues reached €2.1bn, with more than 90% of international sales.